Tag - FPRX

Developments

Five Prime bemarituzumab meets all efficacy endpoints in Phase 2 gastric cancer trial

Five Prime Therapeutics (NASDAQ:FPRX) reported positive topline results from its Phase 2 trial evaluating bemarituzumab, in combination with chemotherapy, in patients with fibroblast growth factor receptor 2b-positive...

November 10, 2020

Executive Moves

Five Prime Therapeutics appoints industry leader, Tom Civik, as CEO

Tom Civik Five Prime Therapeutics (NASDAQ:FPRX) appointed Tom Civik as president, CEO and a director. William Ringo, who served as Five Prime’s chairman and interim CEO since September 2019, will step down as CEO and...

April 14, 2020

Developments

Five Prime misses primary endpoint in pancreatic cancer trial

Five Prime Therapeutics (NASDAQ:FPRX) reported that its Phase 2 trial evaluating cabiralizumab in combination with Opdivo, with and without chemotherapy, in patients with advanced pancreatic cancer failed to meet its...

February 18, 2020

Tag - FPRX

Five Prime bemarituzumab meets all efficacy endpoints in Phase 2 gastric cancer trial

Five Prime Therapeutics appoints industry leader, Tom Civik, as CEO

Five Prime misses primary endpoint in pancreatic cancer trial

General

More